Larimar Therapeutics (LRMR) Capital Expenditures (2013 - 2025)
Larimar Therapeutics (LRMR) posted Capital Expenditures of -$19000.0 for Q4 2025, up 84.43% on a QoQ basis from -$122000.0 in Q3 2025, and down 110.61% year-over-year from $179000.0 in Q4 2024.
Larimar Therapeutics (LRMR) Capital Expenditures (2013 - 2025) Analysis & Trends
Larimar Therapeutics' Capital Expenditures history runs 13 years deep, the most recent figure standing at -$19000.0 for Q4 2025.
- Quarterly Capital Expenditures fell 110.61% year-over-year to -$19000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$73000.0 (down 114.17% YoY) and the FY2025 annual result came in at -$73000.0, down 114.17% from the prior year.
- Capital Expenditures was -$19000.0 for Q4 2025 at Larimar Therapeutics, up from -$122000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $359000.0 in Q3 2024 and bottomed at -$244000.0 in Q3 2021.
- A 5-year average of $45400.0 and a median of -$3000.0 in 2022 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 33000.0% in 2021, while the deepest fall reached 4980.0% in 2021.
- Larimar Therapeutics' Capital Expenditures stood at $324000.0 in 2021, then sank by 101.54% to -$5000.0 in 2022, then surged by 3460.0% to $168000.0 in 2023, then gained by 6.55% to $179000.0 in 2024, then sank by 110.61% to -$19000.0 in 2025.
- Business Quant data shows LRMR's Capital Expenditures at -$19000.0 in Q4 2025, -$122000.0 in Q3 2025, and $82000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 786,000.00 |
| 10 | Larimar Therapeutics | 37.00 Mn | -99.85 Mn | - | -19,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -19,000.00 |
| Dec 31, 2025 | -19,000.00 |
| Sep 30, 2025 | -122,000.00 |
| Sep 30, 2025 | -122,000.00 |
| Jun 30, 2025 | 82,000.00 |
| Jun 30, 2025 | 82,000.00 |
| Mar 31, 2025 | -14,000.00 |
| Mar 31, 2025 | -14,000.00 |
| Dec 31, 2024 | 179,000.00 |
| Dec 31, 2024 | 179,000.00 |
| Sep 30, 2024 | 359,000.00 |
| Sep 30, 2024 | 359,000.00 |
| Jun 30, 2024 | -42,000.00 |
| Jun 30, 2024 | -42,000.00 |
| Mar 31, 2024 | 19,000.00 |
| Mar 31, 2024 | 19,000.00 |
| Dec 31, 2023 | 168,000.00 |
| Dec 31, 2023 | 168,000.00 |
| Sep 30, 2023 | -10,000.00 |
| Sep 30, 2023 | -10,000.00 |